Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: puborectalis who wrote (638)	2/15/1999 1:41:00 AM
From: John Metcalf	Respond to of 2001

Stephen, your surgical brethren are buying and using ADCON-L, FDA approval having been granted some time ago. It is not a tremendous stetch to believe they will buy and use succeeding ADCON products. It is a mistake to refer to Dr. Harmon as a graduate of a second-rate medical school. He is one of the pioneers of the biotech industry. Do a Medline search on "Richard C. Harmon". I found it more impressive than a similar search on "Stephen Karasick". Please add something constructive to this thread. If there is a body of surgical knowledge concerning ADCON products, tell us about it.

To: puborectalis who wrote (638)	2/15/1999 2:08:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2001

>> even the best including the ex-Chairman of Urology at the U of Mich << >> prestigious Doctor of Philosophy in Immunology << >> making more money << Titles, degrees, fancy schools and money. That's O.K., but you're not sounding much like a scientist or like someone who knows the industry. There's an attorney-businessman here at SI that was up something like 60-70% last year with a well-balanced portfolio that included, together with grind-em-outs like SEPR, second- and third-tier biotechs. That's for a year where biotech stunk and second- and third-tier were killed. An attorney. The guy thinks like a scientist, and he has a shrewd business mind. If you stick around, you may learn something from him. Of course, you'd need to listen a bit and read first before coming to conclusions. >> As for GLIA and their drug to decrease peritoneal adhesions...If you ever conversed with your surgical brethren you'd realize that these drugs are not efficacious << Dr. Karasick, you just switched from Adcon-P to "these drugs". That's not very scientific of you, is it? The patent office distinguishes between "these drugs". Certainly, there must be a reason for that? "That thick, wool blanket won't keep me warm, because that thin, cotton one didn't do such last night." >> presenting a paper at a national meeting of surgeons is no big deal << We're agreed there. However, the real worry would have been had they not presented, eh, Dr. Karasick? >> If you ever conversed with your surgical brethren << Look back about 20 posts or so in this thread. You'll find one of your brethren that thinks that the lumbar product is pretty good. Lots of people didn't think that -L would fly. >> Wall Street is strewn with biotech companies that never made it to the FDA final cut << Look around the S.I. archives, Dr. Kurasick, and you'll (1) understand that good, informed investors are doing quite well, and (2) that my enthusiastic comments aren't to be found associated with too many of the companies that you allude to. We work hard here to find good investments. If you have anything of substance, science, to lend to this thread, it will be very welcome.